CL
CLDI.US Calidi Biotherapeutics Inc.
- Market cap
- USD 2.29M
- P/E
- -
- P/B
- 0.54x
- ROE
- -974.0%
- Dividend yield
- 248.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CLDI.US undervalued?
Graham numberThe Graham number of Calidi Biotherapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Calidi Biotherapeutics Inc. fundamental analysis
No fundamental analysis for Calidi Biotherapeutics Inc. yet.
Calidi Biotherapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metast…
Full company profileCalidi Biotherapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Calidi Biotherapeutics Inc. annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 449K | 45.0K | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 355K | -229K | -1.26M | -1.54M | -1.65M | - |
| Operating Income | -6.77M | -10.5M | -23.1M | -29.0M | -21.8M | -20.2M | -16.9M |
| EBITDA | -6.66M | -9.45M | -25.0M | -24.2M | -19.7M | -18.2M | -15.6M |
| Net Income | -7.94M | -10.9M | -25.4M | -29.2M | -22.1M | -19.9M | -15.9M |
| EPS | -43 | -733 | -5,763 | -3,335 | -533 | -74 | -6.42 |
| Balance Sheet | |||||||
| Total Assets | 1.85M | 3.39M | 2.60M | 10.0M | 14.2M | 8.86M | 5.52M |
| Total Liabilities | 24.3M | 26.0M | 53.0M | 18.3M | 12.2M | 5.10M | 3.89M |
| Shareholders' Equity | -22.5M | -22.6M | -50.4M | -8.24M | 1.53M | 3.76M | 1.63M |
| Cash & Short-term Investments | 420K | 2.14M | 372K | 2.05M | 9.59M | 5.60M | 3.95M |
| Total Debt | 11.7M | 5.18M | 5.99M | 7.24M | 7.04M | 2.56M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -4.83M | -7.77M | -13.2M | -27.0M | -19.7M | -21.3M | -14.4M |
| Capital Expenditure | 351K | 206K | 428K | 585K | 16.0K | 120K | 13.3K |
| Free Cash Flow | -5.18M | -7.98M | -13.6M | -27.6M | -19.7M | -21.4M | -14.4M |
| Ratios | |||||||
| ROE | - | - | - | - | -1,443.5% | -529.6% | -974.0% |
| ROA | -428.6% | -322.4% | -979.1% | -291.6% | -156.1% | -224.7% | -287.6% |
| Net Profit Margin | - | -2,435.0% | -56,504.4% | - | - | - | - |
| Debt to Equity | - | - | - | - | 4.59x | 0.68x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Calidi Biotherapeutics Inc. dividends
- Dividend yield
- 248.12%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.67M | 21 | - |
| 2024 | USD 1.67M | 40 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:16 on Jul 31, 2026.
Who owns Calidi Biotherapeutics Inc.
- Insiders 0.61%
- Institutions 2.60%
- Public & others 96.79%
- Shares outstanding 3.68M
- Free float 2.57M
Calidi Biotherapeutics Inc. company profile
- Company name
- Calidi Biotherapeutics Inc.
- Ticker
- CLDI.US
- Exchange
- USA Stocks
- Listed since
- Nov 1, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 4475 Executive Drive, San Diego, CA, United States, 92121
- Phone
- 858 794 9600
- Website
- calidibio.com
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Calidi Biotherapeutics Inc. management
4- Dr. Eric E. Poma Ph.D.CEO & Director · born 1972
- Mr. Andrew C. JacksonCFO & Corporate Secretary · born 1969
- Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D.Head of Technical Operations & Chief Scientific Officer · born 1980
- Dr. Guy Travis Clifton M.D.Chief Medical Officer